Here's Why You Should Retain Inogen Stock in Your Portfolio for Now
INGN's POC demand, new products and international growth support its outlook, while U.S. channel shifts and distributor timing pose risks.
Should Investors Buy Inogen as Low Valuation Meets Execution Risk?
Inogen's steep sales-multiple discount, improving margins and firm international demand clash with U.S. sales and rental weakness.
Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists
INGN cuts its 2026 revenue outlook as U.S. channel pressure weighs, while international growth, new products and cost control offer support.
Inogen Q2 Earnings Beat Estimates, Sales Rise Y/Y, 2026 View Cut
INGN's Q2 revenues rise 3% as international sales climb 14.8%, but U.S. weakness led it to cut its 2026 revenue outlook.
Inogen, Inc. (INGN) Q2 2026 Earnings Call Transcript
Inogen, Inc. (INGN) Q2 2026 Earnings Call Transcript
Inogen Q2 Earnings Call Highlights
Inogen NASDAQ: INGN reported second-quarter 2026 revenue of $95.1 million, up 3% from a year earlier, as international growth, portable oxygen concentrator demand and contributions from newer products offset continued pressure in its U.S. direct-to-consumer business.
Inogen (INGN) Reports Q2 Loss, Tops Revenue Estimates
Inogen (INGN) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.15 per share a year ago.
Here's Why You Should Retain Inogen Stock in Your Portfolio for Now
INGN's POC strength, expanding respiratory portfolio and international momentum support growth, though U.S. revenue pressure remains a key risk.
Here's Why You Should Retain Inogen Stock in Your Portfolio for Now
INGN broadens beyond portable oxygen concentrators into home respiratory care, but U.S. revenues face pressure from channel shifts.
Inogen, Inc. (INGN) Q1 2026 Earnings Call Transcript
Inogen, Inc. (INGN) Q1 2026 Earnings Call Transcript
INGN Stock Dips on Q1 Earnings Miss, Sales Up Y/Y, Gross Margin Improves
Inogen posts higher Q1 revenues and improved gross margin as international portable oxygen demand offsets weaker U.S. sales.
Inogen (INGN) Reports Q1 Loss, Beats Revenue Estimates
Inogen (INGN) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.25 per share a year ago.
